Transcript: I think one of the biggest gaps in the treatment of bladder cancer today is the fact that we have had very limited options until now. We’ve been using the same drug, BCG, for decades now, and there really hasn’t been a lot of new developments until recently. A lot of exciting stuff going on in bladder cancer right now with newer novel therapies, both intravesical as well as IV and systemic therapies for both non-muscle invasive and muscle invasive bladder cancer.
So it’s an exciting time. We’re learning about combination therapies now and how we can mix and match various forms of therapy that have different mechanism of action to have better outcomes and decrease that high recurrence rates that we see in the bladder. And again, more importantly, that decrease the progression rates and non-muscle invasive cancer.
And the muscle invasive bladder cancer group, again, we’re trying to improve outcomes. Surgery oftentimes, or chemoradiation is not completely successful, and when patients metastasize, unfortunately, life is quite limited for them, so we’re constantly looking for better systemic therapies for those patients as well. And again, there’s some really nice developments in combination therapy in that space as well.